
Microsoft has launched Scout, an AI assistant inspired by the OpenClaw framework, designed to enhance productivity within the Microsoft 365 ecosystem. Scout adapts to user preferences, learning from feedback to automate tasks such as calendar management and meeting agenda drafting. Available through the Frontier program, it requires a GitHub Copilot subscription and offers extensive customization options. The assistant includes a policy conformance system to ensure secure operation, addressing concerns about unsupervised AI behavior. Scout is part of Microsoft's broader AI product lineup unveiled at the Build developer conference.
Read originalEarlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
© TechCrunch AIxAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
© TechCrunch AILev Selector · February 13, 2026 · Background
Lev Selector · March 6, 2026 · Background
Skill Leap AI · March 30, 2026 · Background
NVIDIA Blog · April 30, 2026 · Related
Matt Wolfe · May 6, 2026 · Background
Skill Leap AI · May 7, 2026 · Background
Microsoft Research · May 11, 2026 · Background
WIRED AI · May 26, 2026 · Background
The Verge AI · June 2, 2026 · Related
The Rundown AI · June 3, 2026 · Related
WIRED AI · June 5, 2026 · Related
TechCrunch AI · June 30, 2026 · Background
The Verge AI · September 25, 2026 · Background
Microsoft Introduces Scout, an AI Office Assistant
6 developments
OpenAI is scaling back its ambitions as investor appetite for massive AI infrastructure bets cools. The company has lowered its fundraising target from $30 billion to $20 billion, with only $11 billion secured so far against a valuation that has dropped from $1.4 trillion. This retreat signals a growing wariness among Wall Street investors regarding the capital intensity of the AI race, forcing even the most dominant players to adjust their financial expectations.
Exin Therapeutics has demonstrated an AI agent physically controlling a robotic arm to inject drugs into a live mouse's brain. The experiment reveals a critical divergence in model behavior: Anthropic’s Claude Opus refused the procedure due to safety concerns, while Sonnet proceeded. This suggests that as agents gain direct access to physical lab equipment, their alignment and refusal mechanisms become operational realities rather than theoretical safeguards. It marks a shift from AI merely analyzing data to actively manipulating biological systems under human supervision. The team initially tested Claude Opus 5.5, but it halted the injection, citing potential harm. Switching to Claude Sonnet 5 allowed the procedure to complete, though with delays caused by coordinate system glitches. A secondary Opus agent had to fix code errors without knowing a live surgery was underway. Human oversight remains essential as researchers test more complex tasks like craniotomies.